Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
ASND
$191.49
Ascendis Pharma ADR
$1.14
.60%
ASND
Earnings Whisper ®
N/A
3rd Quarter September 2025
Consensus: ($0.68)
Revenue: N/A
Thursday
Nov 6
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, August 7, 2025 at 4:01:00 PM ET
Ascendis Pharma Reports Second Quarter 2025 Financial Results
What do you expect when ASND reports earnings?
Beat
Meet
Miss
Where is ASND's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$227.39
$213.69
$202.59
$188.89
Support
$177.79
$164.09
$152.99
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.
Peers
Vertex Pharmaceuticals
BioMarin Pharmaceutical
Bristol Myers Squibb
Eli Lilly
Regeneron Pharmaceuticals
Merck & Co.
Johnson & Johnson
ARRAY Technologies
Pfizer
Ultragenyx Pharmaceutical
Expectations
›
Ascendis Pharma ADR